DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy Subjects

Intervention: PF-06410293 (Biological); Adalimumab-US (Biological); Adalimumab-EU (Biological)

Phase: Phase 1

Status: Completed

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Summary

This is a Phase 1, double blind (sponsor open), randomized (1: 1:1), parallel group, 3 arm, single dose comparative PK study of adalimumab Pfizer and adalimumab sourced from the US and EU administered subcutaneously (SC) to healthy male and female volunteers

Clinical Details

Official title: Phase 1, Double Blind, Randomized, Parallel-group, 3-arm, Single-dose, Comparative Pharmacokinetic Study Of Pf-06410293 and Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science

Primary outcome:

maximal serum concentration (Cmax)

area under the concentration time curve (AUC) from time 0 to 2 weeks (AUC0-2wk)

Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-T)]

AUC extrapolated to infinity (AUC0inf)

Secondary outcome:

Type, incidence, severity, timing, seriousness and relatedness of treatment emergent adverse events, and abnormalities in laboratory parameters

Incidence of antidrug antibodies (ADA) and neutralizing antibodies (NAb)

maximal serum concentration (Cmax) for adalimumab EU as compared to adalimumab US

area under the concentration time curve (AUC) from time 0 to 2 weeks (AUC0-2wk) for adalimumab EU as compared to adalimumab US

Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-T)] for adalimumab EU as compared to adalimumab US

AUC extrapolated to infinity (AUC0inf) for adalimumab EU as compared to adalimumab US

time to reach the maximum concentration (Tmax)

Apparent clearance (CL/F)

Apparent volume of distribution (Vz/F)

Terminal half-life (T1/2)

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy male and female subjects between the ages of 18 and 45 years, inclusive.

Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood pressure and heart rate measurement, 12 lead ECG and clinical laboratory tests.

- Body Mass Index (BMI) of 19. 0 to 30. 5 kg/m2; and a total body weight >60 kg (132

lbs).

- Chest X ray with no evidence of current, active TB or previous (inactive) TB, general

infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 24 weeks prior to Day 1 and read by a qualified radiologist. Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine,

pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, autoimmune, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

- Previous history of cancer, except for adequately treated basal cell or squamous cell

carcinoma of the skin.

Locations and Contacts

De La Pedraja Radiology Associates, Coral Gables, Florida 33134, United States

SeaView Jacksonville, Jacksonville, Florida 32256, United States

SeaView Reseach Screening Office, Miami, Florida 33134, United States

SeaView Research, Inc., Miami, Florida 33126, United States

SeaView Research, Inc. (Screening Office), Miami, Florida 33134, United States

Vince & Associates Clinical Research, Inc., Overland Park, Kansas 66211, United States

Vince & Associates Clinical Research, Inc., Overland Park, Kansas 66212, United States

Prism Research, LLC, Saint Paul, Minnesota 55114, United States

Additional Information

To obtain contact information for a study center near you, click here.

Starting date: September 2014
Last updated: April 10, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017